Compare Stocks → Gold Set to EXPLODE! (From Gold Safe Exchange) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:BCLINASDAQ:CYTHNASDAQ:ESLANASDAQ:TARA Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBCLIBrainstorm Cell Therapeutics$0.47+9.3%$0.49$0.13▼$3.34$32.12M0.4968,717 shs5,118 shsCYTHCyclo Therapeutics$1.50-0.7%$1.45$0.89▼$2.57$43.08M-0.1895,191 shs18,777 shsESLAEstrella Immunopharma$1.08+4.9%$1.10$0.86▼$33.00$39.54M0.1936,027 shs1,127 shsTARAProtara Therapeutics$2.83-1.4%$3.53$1.04▼$5.24$32.35M1.8218,714 shs155,506 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBCLIBrainstorm Cell Therapeutics+16.85%-1.04%-41.10%+9.72%-84.91%CYTHCyclo Therapeutics-0.66%+3.45%+6.38%-14.29%+26.05%ESLAEstrella Immunopharma+4.85%+2.86%-1.82%-6.10%+107,999,900.00%TARAProtara Therapeutics-1.39%-3.41%-17.49%-2.08%-9.00%Gold Set to EXPLODE! (Ad)Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.Click here now to download the free Precious Metals Buying Guide!MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBCLIBrainstorm Cell Therapeutics0.3847 of 5 stars0.03.00.04.70.00.00.6CYTHCyclo Therapeutics2.9827 of 5 stars3.53.00.00.02.53.30.6ESLAEstrella ImmunopharmaN/AN/AN/AN/AN/AN/AN/AN/ATARAProtara Therapeutics2.4016 of 5 stars3.53.00.00.03.20.80.6Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBCLIBrainstorm Cell Therapeutics2.00HoldN/AN/ACYTHCyclo Therapeutics3.00Buy$3.20113.33% UpsideESLAEstrella ImmunopharmaN/AN/AN/AN/ATARAProtara Therapeutics3.00Buy$26.50836.40% UpsideCurrent Analyst RatingsLatest BCLI, CYTH, TARA, and ESLA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/6/2024TARAProtara TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$23.005/1/2024CYTHCyclo TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$3.004/22/2024CYTHCyclo TherapeuticsAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$2.604/22/2024TARAProtara TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$26.00 ➝ $30.004/8/2024TARAProtara TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$23.003/14/2024TARAProtara TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$23.00(Data available from 5/9/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBCLIBrainstorm Cell TherapeuticsN/AN/AN/AN/A($0.08) per shareN/ACYTHCyclo Therapeutics$1.08M39.89N/AN/A$0.21 per share7.14ESLAEstrella ImmunopharmaN/AN/AN/AN/A($8.27) per shareN/ATARAProtara TherapeuticsN/AN/AN/AN/A$6.01 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBCLIBrainstorm Cell Therapeutics-$17.19M-$0.41N/AN/AN/AN/AN/A-376.40%5/20/2024 (Estimated)CYTHCyclo Therapeutics-$20.06M-$1.31N/AN/AN/A-1,864.03%-4,506.97%-290.83%5/20/2024 (Estimated)ESLAEstrella Immunopharma-$80KN/A0.00∞N/AN/A-23.59%-22.64%N/ATARAProtara Therapeutics-$40.42M-$3.74N/AN/AN/AN/A-58.80%-51.37%8/1/2024 (Estimated)Latest BCLI, CYTH, TARA, and ESLA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails4/1/2024Q4 2023BCLIBrainstorm Cell Therapeutics-$0.15-$0.11+$0.04-$0.11N/AN/A3/18/2024Q4 2023CYTHCyclo TherapeuticsN/A-$0.23-$0.23-$0.23N/A$0.31 million3/13/2024Q4 2023TARAProtara Therapeutics-$1.03-$0.90+$0.13-$0.90N/AN/A2/14/2024Q4 2023ESLAEstrella ImmunopharmaN/A-$0.03-$0.03-$0.03N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBCLIBrainstorm Cell TherapeuticsN/AN/AN/AN/AN/ACYTHCyclo TherapeuticsN/AN/AN/AN/AN/AESLAEstrella ImmunopharmaN/AN/AN/AN/AN/ATARAProtara TherapeuticsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBCLIBrainstorm Cell TherapeuticsN/A0.240.24CYTHCyclo TherapeuticsN/A1.451.42ESLAEstrella ImmunopharmaN/A1.581.58TARAProtara TherapeuticsN/A10.5310.53OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBCLIBrainstorm Cell Therapeutics14.33%CYTHCyclo Therapeutics68.55%ESLAEstrella Immunopharma0.35%TARAProtara Therapeutics38.13%Insider OwnershipCompanyInsider OwnershipBCLIBrainstorm Cell Therapeutics5.45%CYTHCyclo Therapeutics29.78%ESLAEstrella Immunopharma55.10%TARAProtara Therapeutics18.40%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableBCLIBrainstorm Cell Therapeutics2968.34 million64.62 millionOptionableCYTHCyclo Therapeutics828.72 million20.16 millionNo DataESLAEstrella ImmunopharmaN/A36.61 million16.44 millionNot OptionableTARAProtara Therapeutics2611.43 million9.33 millionOptionableBCLI, CYTH, TARA, and ESLA HeadlinesSourceHeadlineHC Wainwright Equities Analysts Decrease Earnings Estimates for Protara Therapeutics, Inc. (NASDAQ:TARA)americanbankingnews.com - May 9 at 6:48 AMProtara Therapeutics (NASDAQ:TARA) Stock Rating Reaffirmed by HC Wainwrightamericanbankingnews.com - May 8 at 1:18 AMBuy Rating Affirmed for Protara Therapeutics Amid Promising Clinical Trials and Market Potential for TARA-002markets.businessinsider.com - May 7 at 12:30 AMTARA Stock Earnings: Protara Therapeutics Misses EPS for Q1 2024investorplace.com - May 2 at 1:06 PMProtara Therapeutics: Q1 Earnings Snapshotsfgate.com - May 2 at 8:35 AMProtara Therapeutics Announces First Quarter 2024 Financial Results and Provides Business Updateglobenewswire.com - May 2 at 8:00 AMProtara Therapeutics (TARA) Price Target Decreased by 11.76% to 27.54msn.com - April 17 at 12:11 PMProtara Therapeutics, Inc. (TARA)finance.yahoo.com - April 15 at 6:45 PMHere's Why Protara Therapeutics (TARA) Is a Great 'Buy the Bottom' Stock Nowzacks.com - April 12 at 10:56 AMBuy Rating for Protara Therapeutics’ TARA-002 Based on Promising Clinical Data and Market Potential in NMIBC Treatmentmarkets.businessinsider.com - April 9 at 2:25 AMProtara Therapeutics Shares Interim Data From Bladder Cancer Study, Raises $45M Via Equitymsn.com - April 5 at 3:10 PMProtara Reaches Alignment With FDA On A Registrational Path Forward For IV Choline Chloridemarkets.businessinsider.com - April 5 at 10:10 AMProtara Announces Positive Data From TARA-002 Trial In Bladder Cancer; Stock Upmarkets.businessinsider.com - April 5 at 10:10 AMProtara Therapeutics Announces Oversubscribed $45 Million Private Placement Financingglobenewswire.com - April 5 at 8:04 AMProtara Therapeutics Announces Alignment with FDA on Registrational Path Forward for IV Choline Chloride in Patients Dependent on Parenteral Nutritionglobenewswire.com - April 5 at 8:02 AMProtara Therapeutics Announces Positive Three-Month Data from TARA-002 Clinical Program in NMIBCglobenewswire.com - April 5 at 8:00 AM3 Stocks That Could Help You Retire on a Private Islandinvestorplace.com - March 23 at 6:00 AMBuy Rating on Protara Therapeutics Backed by Promising TARA-002 Clinical Trials and Significant Market Opportunitymarkets.businessinsider.com - March 13 at 6:27 PMProtara Therapeutics: Q4 Earnings Snapshotchron.com - March 13 at 1:26 PMProtara Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updateglobenewswire.com - March 13 at 8:00 AMTARA Aug 2024 7.500 callfinance.yahoo.com - March 3 at 11:42 PMTARA May 2024 2.500 putfinance.yahoo.com - March 3 at 11:42 PMNon Muscle Invasive Bladder Cancer Pipeline Outlook Report 2024theglobeandmail.com - February 28 at 7:58 PMProtara Therapeutics to Present at the TD Cowen 44th Annual Health Care Conferenceglobenewswire.com - February 28 at 8:00 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsBrainstorm Cell TherapeuticsNASDAQ:BCLIBrainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; Phase II clinical trial for the treatment of progressive multiple sclerosis; and for the treatment of alzheimer's disease, as well as for other neurodegenerative diseases. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.Cyclo TherapeuticsNASDAQ:CYTHCyclo Therapeutics, Inc., a clinical stage biotechnology company, engages in the development of cyclodextrin-based products for the treatment of neurodegenerative diseases. The company's lead drug candidate is Trappsol Cyclo (hydroxypropyl beta cyclodextrin), an orphan drug, which is in Phase III clinical trials for the treatment of Niemann-Pick Type C disease; and in Phase IIb clinical trials for the treatment of Alzheimer's disease. It also sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. The company was formerly known as CTD Holdings, Inc. and changed its name to Cyclo Therapeutics, Inc. in September 2019. Cyclo Therapeutics, Inc. was incorporated in 1990 and is headquartered in Gainesville, Florida.Estrella ImmunopharmaNASDAQ:ESLAEstrella Immunopharma, Inc., a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. is based in EmeryVille, California.Protara TherapeuticsNASDAQ:TARAProtara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy that is in Phase II clinical trial for patients receiving parenteral nutrition. The company is headquartered in New York, New York. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
